Jump to content

Oxford Science Enterprises: Difference between revisions

Add links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
move infobox
Citation bot (talk | contribs)
Bots
5,405,858 edits
Added date. | Use this bot. Report bugs. | Suggested by Anas1712 | #UCB_toolbar
 
(20 intermediate revisions by 15 users not shown)
Line 1: Line 1:
{{Short description|Venture Capital Firm in Oxford, United Kingdom}}
{{Use dmy dates|date=November 2019}}
{{Use dmy dates|date=November 2019}}
{{COI|date=September 2019}}
{{Infobox company
{{Infobox company
| name = Oxford Sciences Enterprises
| name = Oxford Science Enterprises
| logo = Oxford Sciences Innovation Logo.png
| logo = Oxford Sciences Enterprises Logo.svg
| logo_size =
| logo_size =
| logo_alt =
| logo_alt =
| logo_caption =
| logo_caption =
| former_name = Oxford Sciences Innovation (OSI)
| image =
| type = [[Private company]]
| image_size =
⚫
| industry = [[Venture Capital]]
| image_alt =
⚫
| predecessor = [[IP Group]]
| image_caption =
| founded = {{Start date and age|2015}}
| native_name =
| founder = [[David Norwood]] and [[Oxford University]]
| native_name_lang = <!-- Use ISO 639-1 code, e.g. "fr" for French. For multiple names in different languages, use {{Lang|[code]|[name]}}. -->
⚫
| hq_location_city = [[Oxford]]
| romanized_name =
⚫
| hq_location_country = [[United Kingdom]]
| former_name =
| area_served = Oxford
| type = Venture Capital
| key_people = {{Unbulleted list
| traded_as =
| [[Ed Bussey]] (CEO)
| ISIN =
| [[David Norwood]] (cofounder)
⚫
| industry = Venture Capital
}}
| genre =
| fate =
⚫
| predecessor = [[IP Group]]<!-- or: | predecessors = -->
| successor = <!-- or: | successors = -->
| founded = <!-- if known: {{Start date and age|YYYY|MM|DD}} in [[city]], state, country -->
| founder = <!-- or: | founders = -->
| defunct = <!-- {{End date|YYYY|MM|DD}} -->
| hq_location =
⚫
| hq_location_city = Oxford
⚫
| hq_location_country = UK
| num_locations =
| num_locations_year = <!-- Year of num_locations data (if known) -->
| area_served = <!-- or: | areas_served = -->
| key_people = [[Charles R. Conn]] [[David Norwood]]
| products =
| brands =
| production =
| production_year = <!-- Year of production data (if known) -->
| services =
| services =
| revenue =
| aum = $800M (2022)
| revenue_year = <!-- Year of revenue data (if known) -->
| operating_income =
| income_year = <!-- Year of operating_income data (if known) -->
| net_income = <!-- or: | profit = -->
| net_income_year = <!-- or: | profit_year = --><!-- Year of net_income/profit data (if known) -->
| aum = <!-- Only for financial-service companies -->
| assets =
| assets =
| assets_year = <!-- Year of assets data (if known) -->
| assets_year = <!-- Year of assets data (if known) -->
| equity =
| equity_year = <!-- Year of equity data (if known) -->
| owner = <!-- or: | owners = -->
| members =
| members_year = <!-- Year of members data (if known) -->
| num_employees =
| num_employees =
| num_employees_year = <!-- Year of num_employees data (if known) -->
| num_employees_year = <!-- Year of num_employees data (if known) -->
| parent =
| parent =
⚫
| website = {{URL|oxfordscienceenterprises.com}}
| divisions =
| subsid =
| module = <!-- Used to embed other templates -->
| ratio = <!-- Basel III ratio; used for banks only -->
| rating = <!-- Credit rating; used for banks only -->
⚫
| website = {{URL|www.oxfordsciencesinnovation.com/}}
| footnotes =
| ISIN2 =
| trade_name =
}}
}}
'''Oxford Sciences Enterprises''' is an [[Seed capital|early-stage]] [[Venture capital|venture capital firm]] with over $800M in [[Assets under management|AUM]] based in [[Oxford]], UK.<ref>{{Cite web|title=$474M Fund Will Support Oxford University Spinouts|url=https://social.techcrunch.com/2015/05/14/oxford-sciences-innovation-fund/|access-date=2020-06-10|website=TechCrunch|language=en-US}}</ref> It operates in partnership with the [[University of Oxford]], as the university's preferred investor, several prominent financiers back the firm, including [[GV (company)|Google Ventures]], [[Sequoia Capital]], [[Tencent]], [[Huawei]] and [[Invesco]].<ref>{{Cite web|url=https://www.fiercebiotech.com/financials/backing-from-google-ventures-drives-oxford-uni-spinout-fund-past-%C2%A3300m-target|title=Backing from Google Ventures drives Oxford Uni spinout fund past £300M target|website=FierceBiotech|language=en|access-date=2019-09-13}}</ref><ref>{{Cite news|url=https://www.ft.com/content/009252f0-db13-4a7f-bdd8-4e1cebbd939f|title=Oxford Sciences Innovation parts ways with chief executive|newspaper=Financial Times|date=19 January 2020|last1=Walker|first1=Owen}}</ref> The firm uses academic research from the university's science departments to form commercial businesses, also known as [[University spin-off|spin-outs]].<ref name=":0">{{Cite news|url=https://www.telegraph.co.uk/technology/the-valley-of-death/|title=The Valley of Death: the students vying to be millionaires|date=2018-03-18|work=The Telegraph|access-date=2019-09-13|language=en-GB|issn=0307-1235}}</ref><ref>{{Cite web|url=http://www.newelectronics.co.uk/electronics-technology/uk-universities-getting-better-at-commercialising-research/150045/|title=UK universities getting better at commercialising research|website=www.newelectronics.co.uk|access-date=2019-09-13}}</ref><ref name="news.sky.com">{{Cite web|url=https://news.sky.com/story/city-tycoon-spencer-backs-70m-blood-testing-start-up-osler-11586629|title=City tycoon Spencer backs £70m blood-testing start-up Osler|website=Sky News|language=en|access-date=2019-09-13}}</ref>
'''Oxford Science Enterprises''' ('''OSE''') (Previously known as ''Oxford Sciences Innovation'') is a British [[Seed capital|early-stage]] [[Venture capital|venture capital firm]] with over $800M in [[Assets under management |AUM]] based in [[Oxford]], UK.<ref>{{cite news |url=https://news.sky.com/story/oxford-university-spinouts-chief-leaves-months-after-250m-share-sale-12768561 |title=Oxford University spinouts chief leaves months after £250m share sale |publisher=Sky News |date=December 15, 2022}}</ref><ref>{{Cite web|title=$474M Fund Will Support Oxford University Spinouts|url=https://techcrunch.com/2015/05/14/oxford-sciences-innovation-fund/|access-date=2020-06-10|website=TechCrunch|date=14 May 2015 |language=en-US}}</ref> It operates in partnership with the [[University of Oxford]], as the university's preferred investor, several prominent financiers back the firm, including [[GV (company)|Google Ventures]], [[Sequoia Capital]], [[Tencent]], [[Huawei]] and [[Invesco]].<ref>{{Cite web|url=https://www.fiercebiotech.com/financials/backing-from-google-ventures-drives-oxford-uni-spinout-fund-past-%C2%A3300m-target|title=Backing from Google Ventures drives Oxford Uni spinout fund past £300M target|website=FierceBiotech|language=en|access-date=2019-09-13}}</ref><ref>{{Cite news|url=https://www.ft.com/content/009252f0-db13-4a7f-bdd8-4e1cebbd939f|title=Oxford Sciences Innovation parts ways with chief executive|newspaper=Financial Times|date=19 January 2020|last1=Walker|first1=Owen}}</ref>


The firm uses academic research from the university's science departments to form commercial businesses, also known as [[University spin-off|spin-outs]].<ref name=":0">{{Cite news|url=https://www.telegraph.co.uk/technology/the-valley-of-death/|title=The Valley of Death: the students vying to be millionaires|date=2018-03-18|work=The Telegraph|access-date=2019-09-13|language=en-GB|issn=0307-1235}}</ref><ref>{{Cite web|url=http://www.newelectronics.co.uk/electronics-technology/uk-universities-getting-better-at-commercialising-research/150045/|title=UK universities getting better at commercialising research|website=www.newelectronics.co.uk|access-date=2019-09-13}}</ref><ref name="news.sky.com">{{Cite web|url=https://news.sky.com/story/city-tycoon-spencer-backs-70m-blood-testing-start-up-osler-11586629|title=City tycoon Spencer backs £70m blood-testing start-up Osler|website=Sky News|language=en|access-date=2019-09-13}}</ref>
==Founding & Management==

⚫
The company was founded in 2015 by [[David Norwood]], who was previously the founder of the [[IP Group]], which initially invested only in spinoffs from the university's chemistry department.<ref name=":1">{{Cite web|url=http://www.ox.ac.uk/news/2019-02-28-oxford-sciences-innovation-plc-appoints-new-ceo-and-chairman-prepares-next-phase|title=Oxford Sciences Innovation Plc appoints new CEO and Chairman; prepares for next phase of growth {{!}} University of Oxford|website=www.ox.ac.uk |access-date=2019-09-13}}</ref> Oxford Sciences Enterprises initially raised £600m from investors, which included [[Paul Ruddock|Lansdowne Partners]] and [[GV (company)|Google Ventures]].<ref name=":5" /><ref name=":2">{{Cite magazine |url=https://www.bmmagazine.co.uk/get-funded/success-stories/metaboards-secures-5-million-in-funding-led-by-oxford-sciences-innovation/|title=Metaboards secures $5 million in funding led by Oxford Sciences Enterprises |date=2018-06-13 |magazine=Business Matters |access-date=2019-09-13}}</ref><ref name="McKee">{{Cite web|url=http://www.pharmatimes.com/news/evox_raises_35m_for_exosome_therapeutics_1251097|title=Evox raises £35m for exosome therapeutics|last=McKee|first=Selina|date=2018-09-03|website=PharmaTimes |access-date=2019-09-13}}</ref><ref name=":3">{{Cite web|url=https://www.ft.com/content/7cd09b8c-165a-11e6-b197-a4af20d5575e|title=Oxford biotech deals highlight stature of UK university spinouts|last=Ward|first=Andrew|date=May 10, 2016|website=Financial Times |url-status=live|access-date=2019-09-13}}</ref> Google Ventures partners Tom Hulme and Dr Krishna Yeshwant also joined OSI's advisory board, along with Google AI researcher [[Demis Hassabis]], founder of [[DeepMind]].<ref name=":5">{{Cite news|url=https://www.telegraph.co.uk/finance/newsbysector/banksandfinance/11685426/Google-and-Charles-Dunstone-back-Oxford-University-spin-out-fund.html|title=Google and Charles Dunstone back Oxford University spin-out fund|last=Burn-Callander|first=Rebecca|journal=Daily Telegraph|date=2015-06-19|access-date=2019-09-13 |issn=0307-1235}}</ref><ref>{{Cite web|url=https://www.businessinsider.com/google-ventures-europe-second-investment-oxford-sciences-innovation-osi-2015-6|title=Google's European venture capital fund just made its second investment|last=Price|first=Rob|website=Business Insider|access-date=2019-09-13}}</ref>
== History ==
⚫
The company was founded as Oxford Sciences Innovation (OSI) in 2015 by [[David Norwood]], who was previously the founder of the [[IP Group]], which initially invested only in spinoffs from the university's chemistry department.<ref name=":1">{{Cite web|url=http://www.ox.ac.uk/news/2019-02-28-oxford-sciences-innovation-plc-appoints-new-ceo-and-chairman-prepares-next-phase|title=Oxford Sciences Innovation Plc appoints new CEO and Chairman; prepares for next phase of growth {{!}} University of Oxford|website=www.ox.ac.uk |date=28 February 2019 |access-date=2019-09-13}}</ref> Oxford Sciences Enterprises initially raised £600m from investors, which included [[Lansdowne Partners]] and [[GV (company)|Google Ventures]].<ref name=":5" /><ref name=":2">{{Cite magazine |url=https://www.bmmagazine.co.uk/get-funded/success-stories/metaboards-secures-5-million-in-funding-led-by-oxford-sciences-innovation/|title=Metaboards secures $5 million in funding led by Oxford Sciences Enterprises |date=2018-06-13 |magazine=Business Matters |access-date=2019-09-13}}</ref><ref name="McKee">{{Cite web|url=http://www.pharmatimes.com/news/evox_raises_35m_for_exosome_therapeutics_1251097|title=Evox raises £35m for exosome therapeutics|last=McKee|first=Selina|date=2018-09-03|website=PharmaTimes |access-date=2019-09-13}}</ref><ref name=":3">{{Cite web|url=https://www.ft.com/content/7cd09b8c-165a-11e6-b197-a4af20d5575e|title=Oxford biotech deals highlight stature of UK university spinouts|last=Ward|first=Andrew|date=May 10, 2016|website=Financial Times |access-date=2019-09-13}}</ref> Google Ventures partners Tom Hulme and Dr Krishna Yeshwant also joined OSI's advisory board, along with Google AI researcher [[Demis Hassabis]], founder of [[DeepMind]].<ref name=":5">{{Cite news|url=https://www.telegraph.co.uk/finance/newsbysector/banksandfinance/11685426/Google-and-Charles-Dunstone-back-Oxford-University-spin-out-fund.html|title=Google and Charles Dunstone back Oxford University spin-out fund|last=Burn-Callander|first=Rebecca|journal=Daily Telegraph|date=2015-06-19|access-date=2019-09-13 |issn=0307-1235}}</ref><ref>{{Cite web|url=https://www.businessinsider.com/google-ventures-europe-second-investment-oxford-sciences-innovation-osi-2015-6|title=Google's European venture capital fund just made its second investment|last=Price|first=Rob|website=Business Insider|access-date=2019-09-13}}</ref>


[[Charles R. Conn|Charles Conn]], previously CEO of the [[Rhodes House#The Rhodes Trust|Rhodes Trust]] and former McKinsey partner, was appointed CEO in March 2019. Former Google CFO [[Patrick Pichette]] joined him as Chair of the board.<ref name=":1" /> However, Conn departed in November 2019 and Pichette shortly after. OSI's CFO became acting CEO until the appointment of Alexis Dormandy, another former McKinsey partner, in October 2020<ref name="dormandy">{{Cite news|url=https://www.businessinnovationmag.co.uk/oxford-sciences-innovation-appoints-alexis-dormandy-as-ceo/|title=Oxford Sciences Innovation Plc appoints Alexis Dormandy As CEO}}</ref>
[[Charles R. Conn|Charles Conn]], previously CEO of the [[Rhodes House#The Rhodes Trust|Rhodes Trust]] and former McKinsey partner, was appointed CEO in March 2019. Former Google CFO [[Patrick Pichette]] joined him as Chair of the board.<ref name=":1" /> However, Conn departed in November 2019 and Pichette shortly after. OSI's CFO became acting CEO until the appointment of Alexis Dormandy, another former McKinsey partner, in October 2020<ref name="dormandy">{{Cite news|url=https://www.businessinnovationmag.co.uk/oxford-sciences-innovation-appoints-alexis-dormandy-as-ceo/|title=Oxford Sciences Innovation Plc appoints Alexis Dormandy As CEO}}</ref>


In July 2019, The company announced an investment from Chinese telecommunications company [[Huawei]] of £4.1m in OSI shares (approximately 0.7% of the total fund).<ref>{{Cite web|url=https://www.ft.com/content/28892c04-e453-11e9-b112-9624ec9edc59|title=Huawei buys access to UK innovation with Oxford stake|last=Fildes|first=Nic|date=October 2019|website=Financial Times|language=en-GB|access-date=2019-10-08}}</ref>
⚫
== Structure ==
⚫
OSE is structured differently from other venture capital firms, being an evergreen [[patient capital]], privately held company and not bound by an [[Lasting power of attorney|LPA]] .<ref>{{Cite web|url=https://www.weforum.org/agenda/2018/04/patient-capital/|title=The missing ingredient in innovation: patience|website=World Economic Forum|access-date=2019-09-13}}</ref><ref name=":4">{{Cite web|url=https://www.ft.com/content/d6420472-7f0f-11e5-a1fe-567b37f80b64|title=Patient capital overtakes VC for UK tech groups|last=Ahmed|first=Murad|date=November 1, 2015|website=Financial Times|language=en-GB|url-status=live|access-date=2019-09-13}}</ref><ref>{{Cite news|url=https://www.ft.com/content/d6420472-7f0f-11e5-a1fe-567b37f80b64|title=Patient capital overtakes VC for UK tech groups|website=Financial Times|date=November 2015|language=en-GB|url-status=live|access-date=2019-09-13|last1=Ahmed|first1=Murad}}</ref> As such, the company holds long-term investments, pursuing a patient capital model. OSI differentiates itself from classic venture firms because of its relationship with the university.<ref>{{Cite web|url=https://globaluniversityventuring.com/big-deal-osi-grows-to-730m/|title=Big deal: OSI grows to $730m - Global University Venturing|website=globaluniversityventuring.com|date=12 December 2016|access-date=2019-09-13}}</ref> Unlike most university-linked venture firms, Oxford University is a shareholder in the company, with OSI receiving half of the university's stake in the [[intellectual property]] of a spinout.<ref name=":6">{{Cite web|url=https://www.businessinsider.com/oxford-university-ai-startup-diffblue-has-raised-17-million-in-series-a-funding-2017-6|title=An Oxford University artificial intelligence startup has raised £17 million to check code for errors|last=UK|first=Shona Ghosh, Business Insider|website=Business Insider|access-date=2019-09-13}}</ref>


In September 2023 [[Ed Bussey]] was named CEO of the company, and at the same time Jack Edmondson was appointed to the newly created role of CIO.<ref>[https://www.insidermedia.com/news/south-east/new-ceo-vows-to-lead-ose-into-next-phase-of-growth "New CEO vows to lead OSE into next phase of growth]" ''Insider Media''
OSE works with the university's technology transfer office, [[Oxford University Innovation]], which helps manage the intellectual property and patent estate of the university.<ref>{{Cite web|url=https://www.chemistryworld.com/news/nurturing-the-next-biotech-generation/3010258.article|title=Nurturing the next biotech generation|last=March 2019|first=Clare Sansom20|website=Chemistry World|language=en|access-date=2019-09-13}}</ref>
</ref><ref>[https://thebusinessmagazine.co.uk/recruitment-careers-hr/oxford-science-enterprises-announces-new-ceo/ "Oxford Science Enterprises announces new CEO"] ''The Business Magazine''</ref><ref>[https://globalventuring.com/university/ose-brings-in-bussey-as-ceo/ "OSE brings in Bussey as CEO"] ''Global University Venturing''</ref><ref>
[https://www.biocentury.com/article/649105/oxford-science-enterprises-names-new-ceo-first-cio "Oxford Science Enterprises names new CEO, first CIO"] ''Biocentury''</ref>

⚫
== Structure ==
⚫
OSE is structured differently from other venture capital firms, being an evergreen [[patient capital]], privately held company and not bound by a limited partnership agreement.<ref>{{Cite web|url=https://www.weforum.org/agenda/2018/04/patient-capital/|title=The missing ingredient in innovation: patience|website=World Economic Forum|access-date=2019-09-13}}</ref><ref name=":4">{{Cite web|url=https://www.ft.com/content/d6420472-7f0f-11e5-a1fe-567b37f80b64|title=Patient capital overtakes VC for UK tech groups|last=Ahmed|first=Murad|date=November 1, 2015|website=Financial Times|language=en-GB|access-date=2019-09-13}}</ref><ref>{{Cite news|url=https://www.ft.com/content/d6420472-7f0f-11e5-a1fe-567b37f80b64|title=Patient capital overtakes VC for UK tech groups|website=Financial Times|date=November 2015|language=en-GB|access-date=2019-09-13|last1=Ahmed|first1=Murad}}</ref> As such, the company holds long-term investments, pursuing a patient capital model. OSE differentiates itself from classic venture firms because of its relationship with the university.<ref>{{Cite web|url=https://globaluniversityventuring.com/big-deal-osi-grows-to-730m/|title=Big deal: OSI grows to $730m - Global University Venturing|website=globaluniversityventuring.com|date=12 December 2016|access-date=2019-09-13}}</ref> Unlike most university-linked venture firms, Oxford University is a shareholder in the company, with OSE receiving half of the university's stake in the [[intellectual property]] of a spinout.<ref name=":6">{{Cite web|url=https://www.businessinsider.com/oxford-university-ai-startup-diffblue-has-raised-17-million-in-series-a-funding-2017-6|title=An Oxford University artificial intelligence startup has raised £17 million to check code for errors |first=Shona |last=Ghosh |website=Business Insider |access-date=2019-09-13}}</ref>


In July 2019, The company announced an investment from Chinese telecommunications company [[Huawei]] owns £4.1m in OSI shares (approximately 0.7% of the total fund).<ref>{{Cite web|url=https://www.ft.com/content/28892c04-e453-11e9-b112-9624ec9edc59|title=Huawei buys access to UK innovation with Oxford stake|last=Fildes|first=Nic|date=October 2019|website=Financial Times|language=en-GB|url-status=live|archive-url=|archive-date=|access-date=2019-10-08}}</ref>
OSE works with the university's technology transfer office, [[Oxford University Innovation]], which helps manage the intellectual property and patent estate of the university.<ref>{{Cite web|url=https://www.chemistryworld.com/news/nurturing-the-next-biotech-generation/3010258.article|title=Nurturing the next biotech generation |date=March 21, 2019|first=Clare |last=Sansom |website=Chemistry World|language=en|access-date=2019-09-13}}</ref>


== References ==
== References ==
{{reflist}}
<references />


[[Category:Venture capital firms of the United Kingdom]]
[[Category:Venture capital firms of the United Kingdom]]

Latest revision as of 09:43, 4 September 2024

Oxford Science Enterprises
FormerlyOxford Sciences Innovation (OSI)
Company typePrivate company
IndustryVenture Capital
PredecessorIP Group
Founded2015; 9 years ago (2015)
FounderDavid Norwood and Oxford University
Headquarters
Oxford
,
United Kingdom
Area served
Oxford
Key people
AUM$800M (2022)
Websiteoxfordscienceenterprises.com

Oxford Science Enterprises (OSE) (Previously known as Oxford Sciences Innovation) is a British early-stage venture capital firm with over $800M in AUM based in Oxford, UK.[1][2] It operates in partnership with the University of Oxford, as the university's preferred investor, several prominent financiers back the firm, including Google Ventures, Sequoia Capital, Tencent, Huawei and Invesco.[3][4]

The firm uses academic research from the university's science departments to form commercial businesses, also known as spin-outs.[5][6][7]

History

[edit]

The company was founded as Oxford Sciences Innovation (OSI) in 2015 by David Norwood, who was previously the founder of the IP Group, which initially invested only in spinoffs from the university's chemistry department.[8] Oxford Sciences Enterprises initially raised £600m from investors, which included Lansdowne Partners and Google Ventures.[9][10][11][12] Google Ventures partners Tom Hulme and Dr Krishna Yeshwant also joined OSI's advisory board, along with Google AI researcher Demis Hassabis, founder of DeepMind.[9][13]

Charles Conn, previously CEO of the Rhodes Trust and former McKinsey partner, was appointed CEO in March 2019. Former Google CFO Patrick Pichette joined him as Chair of the board.[8] However, Conn departed in November 2019 and Pichette shortly after. OSI's CFO became acting CEO until the appointment of Alexis Dormandy, another former McKinsey partner, in October 2020[14]

In July 2019, The company announced an investment from Chinese telecommunications company Huawei of £4.1m in OSI shares (approximately 0.7% of the total fund).[15]

In September 2023 Ed Bussey was named CEO of the company, and at the same time Jack Edmondson was appointed to the newly created role of CIO.[16][17][18][19]

Structure

[edit]

OSE is structured differently from other venture capital firms, being an evergreen patient capital, privately held company and not bound by a limited partnership agreement.[20][21][22] As such, the company holds long-term investments, pursuing a patient capital model. OSE differentiates itself from classic venture firms because of its relationship with the university.[23] Unlike most university-linked venture firms, Oxford University is a shareholder in the company, with OSE receiving half of the university's stake in the intellectual property of a spinout.[24]

OSE works with the university's technology transfer office, Oxford University Innovation, which helps manage the intellectual property and patent estate of the university.[25]

References

[edit]
  1. ^ "Oxford University spinouts chief leaves months after £250m share sale". Sky News. 15 December 2022.
  2. ^ "$474M Fund Will Support Oxford University Spinouts". TechCrunch. 14 May 2015. Retrieved 10 June 2020.
  3. ^ "Backing from Google Ventures drives Oxford Uni spinout fund past £300M target". FierceBiotech. Retrieved 13 September 2019.
  4. ^ Walker, Owen (19 January 2020). "Oxford Sciences Innovation parts ways with chief executive". Financial Times.
  5. ^ "The Valley of Death: the students vying to be millionaires". The Telegraph. 18 March 2018. ISSN 0307-1235. Retrieved 13 September 2019.
  6. ^ "UK universities getting better at commercialising research". www.newelectronics.co.uk. Retrieved 13 September 2019.
  7. ^ "City tycoon Spencer backs £70m blood-testing start-up Osler". Sky News. Retrieved 13 September 2019.
  8. ^ a b "Oxford Sciences Innovation Plc appoints new CEO and Chairman; prepares for next phase of growth | University of Oxford". www.ox.ac.uk. 28 February 2019. Retrieved 13 September 2019.
  9. ^ a b Burn-Callander, Rebecca (19 June 2015). "Google and Charles Dunstone back Oxford University spin-out fund". Daily Telegraph. ISSN 0307-1235. Retrieved 13 September 2019.
  10. ^ "Metaboards secures $5 million in funding led by Oxford Sciences Enterprises". Business Matters. 13 June 2018. Retrieved 13 September 2019.
  11. ^ McKee, Selina (3 September 2018). "Evox raises £35m for exosome therapeutics". PharmaTimes. Retrieved 13 September 2019.
  12. ^ Ward, Andrew (10 May 2016). "Oxford biotech deals highlight stature of UK university spinouts". Financial Times. Retrieved 13 September 2019.
  13. ^ Price, Rob. "Google's European venture capital fund just made its second investment". Business Insider. Retrieved 13 September 2019.
  14. ^ "Oxford Sciences Innovation Plc appoints Alexis Dormandy As CEO".
  15. ^ Fildes, Nic (October 2019). "Huawei buys access to UK innovation with Oxford stake". Financial Times. Retrieved 8 October 2019.
  16. ^ "New CEO vows to lead OSE into next phase of growth" Insider Media
  17. ^ "Oxford Science Enterprises announces new CEO" The Business Magazine
  18. ^ "OSE brings in Bussey as CEO" Global University Venturing
  19. ^ "Oxford Science Enterprises names new CEO, first CIO" Biocentury
  20. ^ "The missing ingredient in innovation: patience". World Economic Forum. Retrieved 13 September 2019.
  21. ^ Ahmed, Murad (1 November 2015). "Patient capital overtakes VC for UK tech groups". Financial Times. Retrieved 13 September 2019.
  22. ^ Ahmed, Murad (November 2015). "Patient capital overtakes VC for UK tech groups". Financial Times. Retrieved 13 September 2019.
  23. ^ "Big deal: OSI grows to $730m - Global University Venturing". globaluniversityventuring.com. 12 December 2016. Retrieved 13 September 2019.
  24. ^ Ghosh, Shona. "An Oxford University artificial intelligence startup has raised £17 million to check code for errors". Business Insider. Retrieved 13 September 2019.
  25. ^ Sansom, Clare (21 March 2019). "Nurturing the next biotech generation". Chemistry World. Retrieved 13 September 2019.
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Oxford_Science_Enterprises&oldid=1243961545"